Rolfo Christian, Passiglia Francesco, Ostrowski Marcin, Farracho Lúcia, Ondøichová Tereza, Dolcan Ana, Castiglia Marta, Remmen Roy, Papadimitriou Konstantinos, Pauwels Patrick
From the Phase I Early Clinical Trials Unit, Department of Oncology, Antwerp University Hospital, Edegem, Belgium (CR, FP, KP); European Cancer Organisation, Antwerp University Hospital, Edegem, Belgium (MO, LF, TO, AD); Molecular Pathology Unit, Department of Pathology, Antwerp University Hospital, Edegem, Belgium (MC, PP); and the Faculty of Medicine and Health Sciences, Antwerp University Hospital, Edegem, Belgium (RR).
J Am Board Fam Med. 2015 Jan-Feb;28(1):124-33. doi: 10.3122/jabfm.2015.01.140072.
In the past decade the advent of target therapy has led to a silent revolution in the treatment of lung cancer. Thanks to the specificity of their target, new tailored drugs are able to achieve a larger benefit and lower toxicity and provide better quality of life than cytotoxic drugs in a limited number of patients, selected by molecular profile. Nowadays, the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase inhibitor crizotinib, are targeted agents approved for treatment of non-small-cell lung cancer. Family physicians play an important role in the treatment, detection, and management of common toxicities and in providing emotional support. Therefore this review integrates molecular profile assessment with evidence of the efficacy and toxicity of tyrosine kinase inhibitors to provide an updated overview of the treatment of non-small-cell lung cancer, which radically changed after the advent of targeted therapies. It also aims to promote a more intensive and interactive collaboration between specialists and family physicians in the management of all phases of cancer care.
在过去十年中，靶向治疗的出现引发了肺癌治疗领域的一场悄然变革。由于其靶点的特异性，新型定制药物在经分子特征筛选出的有限数量患者中，能够比细胞毒性药物带来更大的益处、更低的毒性，并提供更好的生活质量。如今，表皮生长因子受体酪氨酸激酶抑制剂厄洛替尼和吉非替尼，以及间变性淋巴瘤激酶抑制剂克唑替尼，都是被批准用于治疗非小细胞肺癌的靶向药物。家庭医生在治疗、检测以及常见毒性的管理和提供情感支持方面发挥着重要作用。因此，本综述将分子特征评估与酪氨酸激酶抑制剂的疗效和毒性证据相结合，以提供非小细胞肺癌治疗的最新概述，靶向治疗出现后，该疾病的治疗发生了根本性变化。它还旨在促进专科医生和家庭医生在癌症治疗各阶段管理中进行更密切、更具互动性的合作。
